Woodline Partners LP Buys 86,540 Shares of Insmed, Inc. $INSM

Key Points

• Woodline Partners LP increased its stake in Insmed, Inc. by 53.3%, acquiring an additional 86,540 shares and now holding approximately 0.14% of the company valued at $18.98 million.
• Multiple analysts have raised their price targets for Insmed, with Bank of America setting a target of $109 and Truist Financial increasing theirs to $139, while the average target price among analysts is $139.86.
• Insmed's CEO sold over 129,805 shares at a price of $100.39, which represents a significant decrease in their ownership, highlighting insider transactions amid market activity.

Woodline Partners LP grew its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 53.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 248,770 shares of the biopharmaceutical company's stock after purchasing an additional 86,540 shares during the quarter. Woodline Partners LP owned approximately 0.14% of Insmed worth $18,979,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of INSM. Mercer Global Advisors Inc. ADV bought a new position in shares of Insmed in the fourth quarter valued at approximately $227,000. Cetera Investment Advisers lifted its holdings in shares of Insmed by 15.0% in the fourth quarter. Cetera Investment Advisers now owns 10,154 shares of the biopharmaceutical company's stock valued at $701,000 after purchasing an additional 1,321 shares in the last quarter. Deutsche Bank AG increased its position in shares of Insmed by 76.6% during the fourth quarter. Deutsche Bank AG now owns 488,966 shares of the biopharmaceutical company's stock valued at $33,758,000 after acquiring an additional 212,024 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Insmed by 10.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 105,313 shares of the biopharmaceutical company's stock valued at $7,270,000 after acquiring an additional 10,352 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its position in shares of Insmed by 19.4% during the fourth quarter. Nuveen Asset Management LLC now owns 1,266,630 shares of the biopharmaceutical company's stock valued at $87,448,000 after acquiring an additional 205,473 shares during the last quarter.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the completion of the sale, the insider owned 54,902 shares of the company's stock, valued at $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director directly owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 335,097 shares of company stock valued at $39,721,648. 3.00% of the stock is owned by insiders.

Insmed Price Performance

Insmed stock traded down $0.09 during midday trading on Tuesday, hitting $143.05. 354,912 shares of the company's stock were exchanged, compared to its average volume of 2,751,202. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $149.08. The stock has a 50-day moving average price of $120.32 and a two-hundred day moving average price of $92.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market cap of $30.24 billion, a P/E ratio of -25.05 and a beta of 0.96.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period last year, the firm earned ($1.94) EPS. The company's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

INSM has been the subject of a number of research analyst reports. HC Wainwright increased their price target on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Guggenheim increased their price target on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research report on Monday, September 8th. Truist Financial increased their price target on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Wells Fargo & Company increased their price target on Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a research report on Wednesday, September 3rd. Finally, Leerink Partners increased their price target on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $139.86.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.